Weiss Ratings Reiterates Sell (D-) Rating for Viridian Therapeutics (NASDAQ:VRDN)

Viridian Therapeutics (NASDAQ:VRDN)‘s stock had its “sell (d-)” rating restated by equities researchers at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

A number of other brokerages have also recently issued reports on VRDN. Wells Fargo & Company dropped their target price on shares of Viridian Therapeutics from $27.00 to $26.00 and set an “equal weight” rating for the company in a report on Thursday, August 7th. The Goldman Sachs Group increased their target price on shares of Viridian Therapeutics from $27.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, August 7th. Needham & Company LLC dropped their target price on shares of Viridian Therapeutics from $36.00 to $34.00 and set a “buy” rating for the company in a report on Wednesday, August 6th. Oppenheimer increased their target price on shares of Viridian Therapeutics from $28.00 to $32.00 and gave the company an “outperform” rating in a report on Thursday, August 7th. Finally, Jefferies Financial Group initiated coverage on shares of Viridian Therapeutics in a report on Monday, August 25th. They issued a “buy” rating and a $44.00 target price for the company. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $34.88.

Viridian Therapeutics Trading Up 2.1%

NASDAQ VRDN opened at $21.81 on Wednesday. The stock has a market capitalization of $1.78 billion, a P/E ratio of -5.69 and a beta of 0.49. Viridian Therapeutics has a 52-week low of $9.90 and a 52-week high of $27.20. The firm has a 50-day moving average price of $19.07 and a 200 day moving average price of $15.96. The company has a quick ratio of 11.01, a current ratio of 11.01 and a debt-to-equity ratio of 0.04.

Viridian Therapeutics (NASDAQ:VRDN) last issued its earnings results on Wednesday, August 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.00). Viridian Therapeutics had a negative net margin of 112,806.88% and a negative return on equity of 78.95%. The company had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.05 million. During the same period last year, the company posted ($0.81) earnings per share. The firm’s quarterly revenue was up 4.2% compared to the same quarter last year. Equities research analysts expect that Viridian Therapeutics will post -4.03 EPS for the current year.

Institutional Trading of Viridian Therapeutics

A number of hedge funds have recently bought and sold shares of VRDN. Amalgamated Bank boosted its position in Viridian Therapeutics by 49.7% during the first quarter. Amalgamated Bank now owns 2,531 shares of the company’s stock worth $34,000 after acquiring an additional 840 shares during the last quarter. GAMMA Investing LLC boosted its position in Viridian Therapeutics by 3,892.9% during the first quarter. GAMMA Investing LLC now owns 8,425 shares of the company’s stock worth $114,000 after acquiring an additional 8,214 shares during the last quarter. Sei Investments Co. acquired a new stake in Viridian Therapeutics during the second quarter worth approximately $147,000. Y Intercept Hong Kong Ltd acquired a new stake in Viridian Therapeutics during the second quarter worth approximately $170,000. Finally, Creative Planning acquired a new stake in Viridian Therapeutics during the second quarter worth approximately $179,000.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.